NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhibitors have been proposed as a...

Full description

Bibliographic Details
Main Authors: Galvani, Elena, Sun, Jing, Leon, Leticia G., Sciarrillo, Rocco, Narayan, Ravi S., Tjin Tham Sjin, Robert, Lee, Kwangho, Ohashi, Kadoaki, Heideman, Daniëlle A.M., Alfieri, Roberta R., Heynen, Guus J., Bernards, René, Smit, Egbert F., Pao, William, Peters, Godefridus J., Giovannetti, Elisa
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767465/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767465/

Similar Items